vs
ONESPAWORLD HOLDINGS Ltd（OSW）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
ONESPAWORLD HOLDINGS Ltd的季度营收约是Ultragenyx Pharmaceutical Inc.的1.2倍（$242.1M vs $207.3M），ONESPAWORLD HOLDINGS Ltd净利率更高（5.0% vs -62.0%，领先67.0%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 11.5%），ONESPAWORLD HOLDINGS Ltd自由现金流更多（$14.9M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 7.1%）
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
OSW vs RARE — 直观对比
营收规模更大
OSW
是对方的1.2倍
$207.3M
营收增速更快
RARE
高出14.4%
11.5%
净利率更高
OSW
高出67.0%
-62.0%
自由现金流更多
OSW
多$115.7M
$-100.8M
两年增速更快
RARE
近两年复合增速
7.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $242.1M | $207.3M |
| 净利润 | $12.1M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 6.8% | -54.7% |
| 净利率 | 5.0% | -62.0% |
| 营收同比 | 11.5% | 25.9% |
| 净利润同比 | -16.2% | 3.5% |
| 每股收益（稀释后） | $0.12 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OSWRARE
| Q4 25 | $242.1M | $207.3M | ||
| Q3 25 | $258.5M | $159.9M | ||
| Q2 25 | $240.7M | $166.5M | ||
| Q1 25 | $219.6M | $139.3M | ||
| Q4 24 | $217.2M | $164.6M | ||
| Q3 24 | $241.7M | $139.5M | ||
| Q2 24 | $224.9M | $147.0M | ||
| Q1 24 | $211.2M | $108.8M |
净利润OSWRARE
| Q4 25 | $12.1M | $-128.6M | ||
| Q3 25 | $24.3M | $-180.4M | ||
| Q2 25 | $19.9M | $-115.0M | ||
| Q1 25 | $15.3M | $-151.1M | ||
| Q4 24 | $14.4M | $-133.2M | ||
| Q3 24 | $21.6M | $-133.5M | ||
| Q2 24 | $15.8M | $-131.6M | ||
| Q1 24 | $21.2M | $-170.7M |
营业利润率OSWRARE
| Q4 25 | 6.8% | -54.7% | ||
| Q3 25 | 10.2% | -106.9% | ||
| Q2 25 | 9.2% | -64.8% | ||
| Q1 25 | 7.7% | -102.6% | ||
| Q4 24 | 7.9% | -74.3% | ||
| Q3 24 | 10.3% | -94.6% | ||
| Q2 24 | 8.4% | -79.1% | ||
| Q1 24 | 8.0% | -151.9% |
净利率OSWRARE
| Q4 25 | 5.0% | -62.0% | ||
| Q3 25 | 9.4% | -112.8% | ||
| Q2 25 | 8.3% | -69.0% | ||
| Q1 25 | 7.0% | -108.5% | ||
| Q4 24 | 6.6% | -80.9% | ||
| Q3 24 | 8.9% | -95.7% | ||
| Q2 24 | 7.0% | -89.5% | ||
| Q1 24 | 10.0% | -156.8% |
每股收益（稀释后）OSWRARE
| Q4 25 | $0.12 | $-1.28 | ||
| Q3 25 | $0.23 | $-1.81 | ||
| Q2 25 | $0.19 | $-1.17 | ||
| Q1 25 | $0.15 | $-1.57 | ||
| Q4 24 | $0.13 | $-1.34 | ||
| Q3 24 | $0.20 | $-1.40 | ||
| Q2 24 | $0.15 | $-1.52 | ||
| Q1 24 | $0.21 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $16.3M | $421.0M |
| 总债务越低越好 | $84.0M | — |
| 股东权益账面价值 | $542.6M | $-80.0M |
| 总资产 | $707.1M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资OSWRARE
| Q4 25 | $16.3M | $421.0M | ||
| Q3 25 | $29.6M | $202.5M | ||
| Q2 25 | $35.0M | $176.3M | ||
| Q1 25 | $22.6M | $127.1M | ||
| Q4 24 | $57.4M | $174.0M | ||
| Q3 24 | $48.8M | $150.6M | ||
| Q2 24 | $62.5M | $480.7M | ||
| Q1 24 | $65.4M | $112.3M |
总债务OSWRARE
| Q4 25 | $84.0M | — | ||
| Q3 25 | $85.2M | — | ||
| Q2 25 | $96.2M | — | ||
| Q1 25 | $97.4M | — | ||
| Q4 24 | $98.6M | — | ||
| Q3 24 | $98.7M | — | ||
| Q2 24 | $123.8M | — | ||
| Q1 24 | $138.6M | — |
股东权益OSWRARE
| Q4 25 | $542.6M | $-80.0M | ||
| Q3 25 | $552.8M | $9.2M | ||
| Q2 25 | $548.3M | $151.3M | ||
| Q1 25 | $530.6M | $144.2M | ||
| Q4 24 | $554.5M | $255.0M | ||
| Q3 24 | $540.1M | $346.8M | ||
| Q2 24 | $532.7M | $432.4M | ||
| Q1 24 | $515.5M | $140.3M |
总资产OSWRARE
| Q4 25 | $707.1M | $1.5B | ||
| Q3 25 | $732.6M | $1.2B | ||
| Q2 25 | $731.8M | $1.3B | ||
| Q1 25 | $708.7M | $1.3B | ||
| Q4 24 | $746.4M | $1.5B | ||
| Q3 24 | $734.0M | $1.5B | ||
| Q2 24 | $756.8M | $1.6B | ||
| Q1 24 | $763.6M | $1.3B |
负债/权益比OSWRARE
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | 0.18× | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | 0.18× | — | ||
| Q2 24 | 0.23× | — | ||
| Q1 24 | 0.27× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $20.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $14.9M | $-100.8M |
| 自由现金流率自由现金流/营收 | 6.2% | -48.6% |
| 资本支出强度资本支出/营收 | 2.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.65× | — |
| 过去12个月自由现金流最近4个季度 | $68.4M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流OSWRARE
| Q4 25 | $20.0M | $-99.8M | ||
| Q3 25 | $33.2M | $-91.4M | ||
| Q2 25 | $20.3M | $-108.3M | ||
| Q1 25 | $10.1M | $-166.5M | ||
| Q4 24 | $16.6M | $-79.3M | ||
| Q3 24 | $28.6M | $-67.0M | ||
| Q2 24 | $18.7M | $-77.0M | ||
| Q1 24 | $15.0M | $-190.7M |
自由现金流OSWRARE
| Q4 25 | $14.9M | $-100.8M | ||
| Q3 25 | $27.6M | $-92.7M | ||
| Q2 25 | $17.6M | $-110.7M | ||
| Q1 25 | $8.4M | $-167.8M | ||
| Q4 24 | $13.2M | $-79.5M | ||
| Q3 24 | $27.5M | $-68.6M | ||
| Q2 24 | $17.6M | $-79.0M | ||
| Q1 24 | $13.7M | $-193.9M |
自由现金流率OSWRARE
| Q4 25 | 6.2% | -48.6% | ||
| Q3 25 | 10.7% | -58.0% | ||
| Q2 25 | 7.3% | -66.5% | ||
| Q1 25 | 3.8% | -120.5% | ||
| Q4 24 | 6.1% | -48.3% | ||
| Q3 24 | 11.4% | -49.2% | ||
| Q2 24 | 7.8% | -53.7% | ||
| Q1 24 | 6.5% | -178.2% |
资本支出强度OSWRARE
| Q4 25 | 2.1% | 0.5% | ||
| Q3 25 | 2.2% | 0.8% | ||
| Q2 25 | 1.1% | 1.5% | ||
| Q1 25 | 0.8% | 1.0% | ||
| Q4 24 | 1.5% | 0.1% | ||
| Q3 24 | 0.5% | 1.2% | ||
| Q2 24 | 0.5% | 1.4% | ||
| Q1 24 | 0.6% | 3.0% |
现金转化率OSWRARE
| Q4 25 | 1.65× | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 1.02× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 1.15× | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 1.19× | — | ||
| Q1 24 | 0.71× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OSW
| Services | $197.3M | 82% |
| Products | $44.8M | 18% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
